Evaluation effect of treatment with IM D3 on clinical, paraclinical symptoms and signs and inhospital outcome at patient admitted with coovid19

Evaluation effect of treatment with IM(intramuscular) D3 on clinical, paraclinical symptoms and signs and in-hospital outcome at patient admitted with coovid19

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200411047024N1

Enrollment

100

Registered

2020-04-29

Start date

2020-05-21

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COIVD-19 patient. covid-19, virus identified

Interventions

Intervention 1: Intervention group: Intramuscular Injection of 300 milligrams of vitamin D at the beginning of the week, as well as another dose at the beginning of the week. Intervention 2: Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individual satisfaction to participate in the project Confirmation of covid-19 disease by CPR test

Exclusion criteria

Exclusion criteria: Vitamin D levels are more than 30 Nanograms /milliliter

Design outcomes

Primary

Measure	Time frame
Clinical course. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: By recording information about the variables defined from the patients' hospital records.;Paraclinical. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Registration of patient's laboratory information and CT scan.;Outcome. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Doctor's approval and death certificate.	—

Measure

Time frame

Clinical course. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: By recording information about the variables defined from the patients' hospital records.;Paraclinical. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Registration of patient's laboratory information and CT scan.;Outcome. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Doctor's approval and death certificate.

—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: End of hospitalization. Method of measurement: Hospital file.;Severe chest pain. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Ask the patient.;Severe shortness of breath. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Ask the patient.;How many days after hospitalization they died. Timepoint: End of hospitalization. Method of measurement: ask the patient.	—

Measure

Time frame

Duration of hospitalization. Timepoint: End of hospitalization. Method of measurement: Hospital file.;Severe chest pain. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Ask the patient.;Severe shortness of breath. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Ask the patient.;How many days after hospitalization they died. Timepoint: End of hospitalization. Method of measurement: ask the patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactErfan Kazemi

Shahroud University of Medical Sciences

kazemi.e@shmu.ac.ir+98 23 3239 5054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026